Symbiofilm Trial in Allergic Kids (SYMBIOFILM-TAK)

CompletedOBSERVATIONAL
Enrollment

186

Participants

Timeline

Start Date

February 14, 2022

Primary Completion Date

November 3, 2022

Study Completion Date

November 3, 2022

Conditions
Common ColdAllergy
Interventions
DEVICE

Healsea® Children

Children will be administered Healsea Children , one puff (1-2 sec) in each nostril twice a day for 10 days on top of conventional therapies, as needed

OTHER

Conventional therapies for common cold

Children will receive conventional therapies for common cold, nasal irrigation excluded (antipyretics, mucolytics, decongestants, antitussives, systemic and topical corticosteroids, antibiotics)

Trial Locations (15)

15-010

Research Site, Bialystok

15-430

Research Site, Bialystok

85-048

Research Site, Bydgoszcz

21-003

Research Site, Dys

95-015

Research Site, Głowno

30-644

Research Site, Krakow

20-093

Research Site, Lublin

20-141

Research Site, Lublin

20-552

Research Site, Lublin

20-803

Research Site, Lublin

20-865

Research Site, Lublin

35-061

Research Site, Rzeszów

33-100

Research Site, Tarnów

04-314

Research Site, Warsaw

18-402

Research Site, Łomża

Sponsors
All Listed Sponsors
lead

Lallemand Pharma AG

INDUSTRY

NCT05034328 - Symbiofilm Trial in Allergic Kids (SYMBIOFILM-TAK) | Biotech Hunter | Biotech Hunter